SCHEMBL6232240

SCHEMBL6232240

Cc1ccc(S(=O)(=O)c2ccccc2S(=O)(=O)N=CN(C)C)cc1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.67
LMNA P02545 1/20 0.67
HTR6 P50406 2/20 0.41
C5AR1 P21730 1/20 0.41
ALDH1A1 P00352 6/20 0.40
POLB P06746 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
BCAT1 P54687 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7262048 1.00 GAA (0.67) GAALMNAHTR6C5AR1ALDH1A1
SCHEMBL6228574 0.83 GAA (0.46) GAALMNAHTR6ALDH1A1HTT
SCHEMBL6228572 0.83 GAA (0.46) GAALMNAHTR6ALDH1A1HTT
SCHEMBL15761364 0.81 GAA (1.00) GAALMNAC5AR1ALDH1A1POLB
SCHEMBL29751607 0.81 GAA (1.00) GAALMNAC5AR1ALDH1A1POLB
SCHEMBL489379 0.79 LMNA (0.58) GAALMNAC5AR1ALDH1A1POLB
SCHEMBL31000980 0.79 GAA (0.68) GAAHTR6C5AR1ALDH1A1CA12
SCHEMBL11853033 0.79 GAA (0.68) GAAHTR6C5AR1ALDH1A1CA12
SCHEMBL6229583 0.76 LMNA (0.54) GAALMNAC5AR1ALDH1A1POLB
SCHEMBL6229585 0.76 LMNA (0.54) GAALMNAC5AR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1076651-B1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA GMBH (DE) 2005-04-20 EP disclosed
US-6573288-B1 Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-06-03 US disclosed
EP-1076651-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT Aventis Pharma Deutschland GmbH (DE) 2001-02-21 EP disclosed
WO-1999057102-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-11-11 WO disclosed